Company intelligence / Profile preview

Exbaq LLC

Bethesda, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Preclinical vaccine demonstrates protection against multiple antibiotic-resistant Gram-positive bacteria (e.g., MRSA, VRE), Gram-negative bacteria (e.g., ESBL E. coli, CR Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa), and fungi (e.g., Candida albicans, mucormycosis) in mouse models of blood and lung infections, with efficacy within 24 hours lasting up to 28 days.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Beyond the preview

Go deeper on Exbaq LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exbaq LLC.

Explore the full profile